Trial results for a study characterizing SARS-CoV-2-specific immunity in individuals who have recovered from COVID-19 were posted on ClinicalTrials.gov on 2026-01-12, involving 760 participants.
Background
COVID-19, caused by the SARS-CoV-2 virus, has impacted global health significantly. Understanding the immune response in individuals who have recovered from the disease is vital for advancing diagnostic tools, developing effective vaccines, and guiding future treatment strategies. Characterizing SARS-CoV-2-specific immunity helps differentiate natural infection responses from vaccine-induced immunity, providing critical data for public health efforts.
Trial design
This completed observational study enrolled 760 participants to investigate conditions including SARS-CoV-2 and COVID-19. The study aimed to characterize SARS-CoV-2-specific immunity in individuals who have recovered from COVID-19. No specific interventions were listed as part of this study, focusing instead on understanding the body's immune response post-infection.
Key results
The trial reported key measurements related to SARS-CoV-2-specific antibody binding response rates (BAMA IgG1) among an America Cohort, categorized by region and enrollment group:
- For SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort:
- Group 1A reported 15 Participants and 26 Participants.
- Group 1B reported 3 Participants and 11 Participants.
- Group 1C reported 16 Participants and 33 Participants.
- Group 1D reported 18 Participants and 33 Participants.
- Group 2A reported 21 Participants and 36 Participants.
- Group 2B reported 25 Participants.
- Group 3 reported 49 Participants.
What this means
The posted results provide specific counts of participants exhibiting SARS-CoV-2-specific antibody binding responses (BAMA IgG1) across various regional and enrollment groups within the America Cohort. This data contributes to the broader understanding of how immunity develops and persists in individuals who have recovered from COVID-19. Such characterization is fundamental for researchers working to develop more effective diagnostic tests, vaccines, and treatments by providing insights into the natural immune landscape following infection.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04403880, titled "Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19", were posted on 2026-01-12 on clinicaltrials.gov.